Option chain shows key data for Aligos Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aligos Therapeutics.

Aligos Therapeutics (NASDAQ:ALGS) Stock, Option Chain

Aligos Therapeutics

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Biotech

Earnings

Earnings Beats

News

Penny Stocks

Markets

Analyst Ratings

Trading Ideas

General

ACRV

ALGS

BEAM

RAPT

Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD).

Beam Therapeutics Begins Dosing in Phase I/II AATD Study

Small Cap

Pre-Market Outlook

Movers

AULT

CDMO

CLEU

CLIN

GDHG

HPCO

MOMO

SLDB

SNOA

SVFD

THAR

TRKA

XCUR

Shares of  Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter.

Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

AUVI

BRSH

BSFC

HITI

IONM

KRON

LGMK

MGOL

MNOV

MOTS

MURA

OPTX

PBTS

SGBX

WLGS

YOSH

Shares of  Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results.

Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket

Aligos Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Truist Securities boosted the price target for Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) from $22 to $26. Truist Securities analyst Jasper Bibb maintained a Buy rating. Universal Technical Institute shares closed at $19.89 on Wednesday. <a href="https://www.benzinga.com/quote/UTI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel increased the price target for Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) from $195 to $205. Stifel analyst Erik Rasmussen maintained a Buy rating. Digital Realty Trust shares closed at $185.91 on Wednesday. <a href="https://www.benzinga.com/quote/DLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities raised Wix.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) price target from $190 to $220. B. Riley Securities analyst Naved Khan maintained a Buy rating. Wix.com shares settled at $210.27 on Wednesday. <a href="https://www.benzinga.com/quote/WIX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) price target from $140 to $165. Wells Fargo analyst Zachary Fadem maintained an Equal-Weight rating. Williams-Sonoma shares closed at $175.04 on Wednesday. <a href="https://www.benzinga.com/quote/WSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt increased NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) price target from $200 to $220. Rosenblatt analyst Hans Mosesmann maintained a Buy rating. Nvidia shares closed at $145.89 on Wednesday.  <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS boosted Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) price target from $75 to $80. UBS analyst William Appicelli maintained a Buy rating. Spire shares closed at $68.39 on Wednesday. See how other analysts view this stock.</li>
<li>Guggenheim cut the price target for AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) from $190 to $189. Guggenheim analyst Ali Faghri maintained a Buy rating. AutoNation shares settled at $164.85 on Wednesday. <a href="https://www.benzinga.com/quote/AN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen boosted Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target from $290 to $340. TD Cowen analyst J. Derrick Wood maintained a Hold rating. Salesforce shares closed at $325.70 on Wednesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group increased the price target for The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) from $138 to $142. Evercore ISI Group analyst Michael Binetti maintained an Outperform rating. TJX shares closed at $119.74 on Wednesday. <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $180 to $190. Deutsche Bank analyst Brad Zelnick maintained a Buy rating. Snowflake shares closed at $129.12 on Wednesday. <a href="https://www.benzinga.com/quote/snow/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NVDA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21135115/image-226-1024x549.png" alt="" class="wp-image-659589" style="width:718px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21135115/image-226-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21135115/image-226-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21135115/image-226-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21135115/image-226.png 1242w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42119232/ross-stores-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Ross Stores Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Price Target

NVDA

SNOW

Nvidia To Rally More Than 50%? Here Are 10 Top Analyst Forecasts For Thursday

Legal

GOOG

GOOGL

U.S. Justice Department Seeks To Unwind Google's Anthropic Deal

Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares are trading higher Thursday after the company announced that the Japan Patent Office granted a composition of matter patent for its lead asset, AZD1656. Here&#8217;s <a href="https://www.benzinga.com/quote/CDT/news">what you need to know.</a>
What To Know: AZD1656 is a glucokinase activator designed to target a range of autoimmune disorders. The patent approval in Japan comes after a similar patent was granted in Australia, marking continued progress in securing intellectual property protections for the company&#8217;s assets.
&#8220;This approval represents another significant milestone in our efforts to maximize the value of our intellectual property portfolio,&#8221; said David Tapolczay, CEO of Conduit Pharmaceuticals.
See Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42119232/ross-stores-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Ross Stores Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
 AZD1656 is part of Conduit&#8217;s strategy to address unmet medical needs, particularly in diseases like Lupus and ANCA Vasculitis. Conduit Pharmaceuticals is also working on other assets, including AZD5658 and AZD5904, to expand its portfolio in the autoimmune space.
&#8220;The granting of this patent in Japan, one of the world&#8217;s largest pharmaceutical markets, underscores the strength of our scientific and intellectual property strategy. We look forward to securing additional approvals in other major markets, further enhancing our global patent coverage and bolstering our out-licensing opportunities,&#8221; Tapolczay added.
CDT Price Action: Conduit Pharmaceuticals shares were up 20.4% at 11 cents at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21121818/CDT-1024x548.png" alt="" class="wp-image-659391" style="width:434px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21121818/CDT-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21121818/CDT-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21121818/CDT-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21121818/CDT.png 1129w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42118680/elon-musk-promises-40-minute-flights-from-nyc-to-shanghai-will-prices-make-it-accessible-to-all">Elon Musk Promises 40-Minute Flights from NYC To Shanghai – Will Prices Make It Accessible To All?</a></li>
</ul>
Image Via Shutterstock.

What's Going On With Conduit Pharmaceuticals Shares Today?

Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are trading higher on Thursday. The company&#8217;s shares may be moving higher in response to its acquisition target Atomic Alchemy which signed a Memorandum of Understanding (MOU) with Zeno Power. Here&#8217;s what you <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42092578/oklo-stock-slides-as-short-seller-sets-sights-on-altman-backed-nuclear-startup">need to know</a>.
What To Know: The goal of the MOU is for Atomic Alchemy to provide Zeno Power with radioisotopes like strontium-90 and americium-241 to power Zeno&#8217;s Radioisotope Power Systems (RPSs).
These systems generate energy from the heat emitted by radioisotopes, powering critical applications such as space exploration and national defense.
&#8220;We are thrilled to be working with Atomic Alchemy and Oklo to advance our fuel supply chain efforts and recover radioisotopes that otherwise would be waste,&#8221; said Harsh S. Desai, Chief Commercialization Officer at Zeno Power. 
&#8220;This partnership aims to expand access to critical isotopes, accelerating our work to meet the growing demand for reliable, persistent energy solutions from the ocean floor to the lunar surface.&#8221;
Previously, Oklo has proposed to acquire Atomic through an all-stock transaction. 
Related Link: <a href="https://www.benzinga.com/news/large-cap/24/11/42094649/nvidia-stock-historically-drops-in-december-after-q3-earnings">Nvidia Stock Historically Drops In December After Q3 Earnings</a>
OKLO Price Action: At the time of writing, Oklo shares are trading 15.8% higher at $24.27, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Oklo, Inc.

OKLO

What's Going On With Oklo Shares Thursday?

WIIM

BIDU

Baidu shares are trading lower. The company reported Q3 financial results.

Hewlett Packard shares are trading higher after RWE announced it will bolster its renewable energy with HPE's AI weather modeling.

Virgin Galactic Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) short percent of float has fallen 3.11% since its last report. The company recently reported that it has 6.90 million shares sold short, which is 23.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Virgin Galactic Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732214720_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Virgin Galactic Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Virgin Galactic Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Virgin Galactic Hldgs's peer group average for short interest as a percentage of float is 6.16%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SPCE

(SPCE) - Analyzing Virgin Galactic Hldgs's Short Interest

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 5.45% since its last report. The company recently reported that it has 21.85 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732214715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 8.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(CVS) - Analyzing CVS Health's Short Interest

H&amp;R Block's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) short percent of float has fallen 8.29% since its last report. The company recently reported that it has 10.19 million shares sold short, which is 12.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>H&amp;R Block Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732214710_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for H&amp;R Block has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing H&amp;R Block's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, H&amp;R Block's peer group average for short interest as a percentage of float is 4.55%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(HRB) - Analyzing H&R Block's Short Interest

<a href="https://www.bloomberg.com/news/articles/2024-11-21/ken-griffin-says-he-s-open-to-selling-minority-stake-in-citadel">https://www.bloomberg.com/news/articles/2024-11-21/ken-griffin-says-he-s-open-to-selling-minority-stake-in-citadel</a>
&nbsp;
Ken Griffin said he would consider selling a piece of <a href="https://www.bloomberg.com/quote/9869818Z:US">Citadel</a>, the $65 billion multistrategy hedge fund he founded in 1990.
"We would be open to the possibility of selling a minority stake in Citadel at some point in the future," he said in an interview with Bloomberg on Thursday at the Economic Club of New York.

Macro Economic Events

Economics

'Ken Griffin Says He's Open to Selling Minority Stake in Citadel' - Bloomberg News

CTVA

Corteva shares are trading higher after Keybanc maintained an Overweight rating on the stock and raised its price target from $66 to $69.

TopBuild shares are trading higher. The company announced it will acquire Metro Supply Company.

Cameco shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from C$75 to C$90.

CYBR

CyberArk Software shares are trading higher after the company announced it secured a QC1 certification in Italy to boost its cloud security for the public sector.

Zscaler shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $200 to $220.

Wix.com shares are trading higher after multiple firms maintained Buy ratings on the stock and raised their respective price targets.

Goldman Sachs analyst Michael Ng maintained a Buy rating on Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a price target of $50.
On November 20, 2024, Comcast announced <a target="_blank" href="https://www.benzinga.com/news/global/24/11/42081224/comcast-plans-major-cable-networks-spinoff-msnbc-and-cnbc-to-form-new-public-company-report" rel="noreferrer noopener">plans to spin off</a> select cable networks and digital assets into a new publicly traded entity called SpinCo.
The proposed spin-off aims to streamline Comcast&#8217;s operations and enhance growth by separating its cable networks and complementary digital assets from its broader media and streaming divisions.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42116366/taiwan-semiconductor-plans-new-factories-annually-boosting-domestic-chip-production" rel="noreferrer noopener">Taiwan Semiconductor Plans New Factories To Boost Domestic Chip Production</a>
SpinCo assets generated approximately $7 billion in trailing twelve-month (TTM) revenue ending September 30, 2024, with an estimated EBITDA between $2 billion and $3 billion, the analyst said.
About 75% of SpinCo&#8217;s portfolio will focus on news and sports, while the remaining 25% covers general entertainment.
Comcast expects SpinCo to maintain a traditional cable network EBITDA margin of around 30%, driven by reduced Peacock-related losses and sports licensing costs.
Post-spin, Comcast&#8217;s remaining media assets (RemainCo) will include NBC broadcast, Peacock, regional sports networks, and Sky, generating an estimated $40 billion in annual revenue.
Peacock will likely remain largely unaffected by the spin, as only 2% of its content originates from SpinCo, while 98% will continue to come from RemainCo.
The spin-off positions SpinCo to pursue growth through organic initiatives and mergers or acquisitions, with a dedicated management team and tailored operational focus.
Mark Lazarus, the current chairman of NBCUniversal Media Group, will serve as SpinCo&#8217;s CEO, and Anand Kini, NBCUniversal&#8217;s CFO, will become SpinCo&#8217;s CFO and COO. Comcast expects the transaction to close within a year, pending regulatory approvals.
Ng highlighted the spin-off as a strategic move to refine Comcast&#8217;s focus on core growth drivers, including residential broadband, wireless services, and streaming.
SpinCo&#8217;s creation will likely improve CNBC and MSNBC monetization through digital subscription models and potential affiliate fee adjustments.
Ng views the separation as accretive to revenue growth while maintaining Comcast&#8217;s leverage neutrality.
Risks to the strategy include intensified cord-cutting, rising programming costs, and competitive pressures from streaming platforms.
Despite these challenges, Ng expects the spin-off to unlock shareholder value and position both SpinCo and RemainCo for sustainable growth.
Ng projected fiscal 2024 revenue of $123.42 billion and EPS of $4.24. The analyst estimates fiscal 2025 revenue of $123.43 billion and EPS of $4.43.
Price Action: CMCSA stock is up 1.59% at $43.68 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42071334/apples-100-million-gamble-tech-giant-moves-to-lift-indonesias-iphone-ban" target="_blank" rel="noreferrer noopener">Apple&#8217;s $100 Million Gamble, Tech Giant Moves to Lift Indonesia&#8217;s iPhone Ban</a></li>
</ul>
Photo by rarrarorro on Shutterstock

Reiteration

Tech

CMCSA

Comcast's Spin-Off to Boost Broadband and Streaming Growth: Goldman Sachs

Elon Musk and Jeff Bezos,&nbsp;two of the&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/41813356/elon-musks-net-worth-soars-by-26-5-billion-in-single-day-after-tesla-stock-surges-post-trump-vic" target="_blank" rel="noopener">world&#8217;s richest people,</a>&nbsp;entered a <a href="https://www.benzinga.com/markets/equities/24/11/42105450/elon-musk-says-amazon-founder-jeff-bezos-urged-tesla-spacex-investors-to-dump-stakes-predicting-trumps-loss">social media sparring</a> match on Thursday.
What Happened: The controversy began when Musk accused Bezos of urging &#8220;everyone&#8221; to sell shares of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ahead of the 2024 presidential election. Musk supported Donald Trump during the presidential stakes, contributing hundreds of millions of dollars to Trump&#8217;s election efforts.
&#8220;Just learned tonight at Mar-a-Lago that Jeff Bezos was telling everyone that @realDonaldTrump would lose for sure, so they should sell all their Tesla and SpaceX stock &#x1f92d;,&#8221; Musk <a href="https://x.com/elonmusk/status/1859483544612913376">posted</a> on his social media platform, X. The post garnered over 29 million views.
Bezos responded nearly nine hours later.
&#8220;Nope. 100% not true,&#8221; the Amazon founder succinctly <a href="https://x.com/JeffBezos/status/1859615862984167549">replied</a>. 
It is unclear whether the billionaire entrepreneur plans to pursue legal action against Musk.
Tesla&#8217;s stock has far outperformed the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) since <a href="https://www.benzinga.com/markets/asia/24/11/41768811/donald-trump-wins-47th-presidency-us-futures-up-europe-up-asia-mixed-crude-falls-and-dollar-strength">Trump&#8217;s election win</a> on Nov. 5. Tesla shares are trading up 35%, breaking the $1 trillion mark, while the benchmark has gained 2.97%.
Musk is the largest shareholder of Tesla. While Musk did not start the company, he has served as CEO since 2008.
Musk and Bezos&#8217; rivalry stretches decades. Musk is the principal shareholder of SpaceX while Bezos owns Blue Origin, two space exploration companies.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">Alphabet Bleeds Over $120 Billion In Market Value, Eyes Worst Day In 10 Months After DOJ Demands Google Chrome Sale</a></li>
</ul>
Photos: lev radin and Kathy Hutchins on Shutterstock

Entertainment

Equities

Social Media

Politics

TSLA

Jeff Bezos Denies Elon Musk's Allegation That He Told People To Sell Tesla Stock: '100% Not True'

SEC Chair Gensler resigns on Jan 20, 2025, ending his tough stance on crypto regulation. Trump plans to replace him due to concerns over stifling innovation.
Securities and Exchange Commission Chair Gary Gensler announced Thursday that he will resign Jan. 20, 2025, coinciding with the inauguration of President-elect Donald Trump.
Gensler&#8217;s tenure has been marked by a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41993524/gary-gensler-hints-at-ending-his-stint-as-sec-chair-defends-crypto-regulation-agenda">stringent regulatory approach</a> toward cryptocurrencies, drawing criticism from the industry.
What Happened: "I thank President Biden for entrusting me with this incredible responsibility. The SEC has met our mission and enforced the law without fear or favor,&#8221; Gensler said in a press release on Thursday.
Appointed on Apr. 17 2021, Gensler brought extensive experience from his previous role as chair of the Commodity Futures Trading Commission.
 His leadership at the SEC was characterized by a firm stance on digital assets, emphasizing investor protection and market integrity.
Gensler frequently likened the cryptocurrency market to the <a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36358607/crypto-wild-west-hurts-investors-sec-chair-says-bankruptcy-court-queues-are-crowded">&#8220;Wild West,&#8221; advocating for comprehensive oversight</a>. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116475/paying-6-24-million-for-a-duct-taped-banana-justin-sun-did-just-that-and-now-hell-eat-it-as-part-of-this-unique-artistic-experience">Paying $6.24 Million For A Duct-Taped Banana? Justin Sun Did Just That — And Now He&#8217;ll Eat It &#8216;As Part Of This Unique Artistic Experience&#8217;</a>
He asserted that many digital assets functioned as securities and should be regulated accordingly. 
Under his direction, the SEC initiated numerous enforcement actions against major crypto entities, including lawsuits <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40568347/after-binance-and-coinbase-gary-gensler-led-sec-set-to-lock-horns-with-crypto-exchange-kra">against Coinbase</a> and Binance for allegedly operating unregistered securities exchanges.
This rigorous approach faced opposition from industry stakeholders and some lawmakers, who argued that it stifled innovation and lacked clear regulatory guidelines. 
In November, the American Securities Association <a href="https://www.americansecurities.org/post/asa-calls-on-sec-chair-gensler-to-immediately-step-down">called</a> for Gensler&#8217;s immediate resignation, citing concerns over his regulatory methods.
Trump has been vocal about his <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41680397/who-will-replace-gary-gensler-the-top-candidates-for-sec-chair-after-the-election">intention to replace Gensler</a>, criticizing his handling of cryptocurrency regulation.
Earlier in July, Trump said, &#8220;I will <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40018935/trumps-bitcoin-conference-pledge-can-he-really-fire-sec-chair-gensler">fire Gary Gensler on day one</a>,&#8221; signaling a potential shift in the SEC&#8217;s approach to digital assets under the incoming administration.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114875/coinbase-ceo-brian-armstrong-stands-out-as-candidate-for-donald-trumps-reported-crypto-czar-position-cardano-co-founder-says">Coinbase CEO Brian Armstrong &#8216;Stands Out&#8217; As Candidate For Donald Trump&#8217;s Reported &#8216;Crypto Czar&#8217; Position, Cardano Co-Founder Says</a></li>
</ul>
Image: Flickr

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Regulations

Gary Gensler To Step Down As SEC Chair On Trump's Inauguration Day

KLA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NYSE">KLAC</a>) short percent of float has fallen 8.47% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KLA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732213823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KLA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KLA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KLA's peer group average for short interest as a percentage of float is 7.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

KLAC

(KLAC) - Analyzing KLA's Short Interest

Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report) and keeping the price target at $75.00...

Promising Prospects for Aligos Therapeutics' ALG-000184 in Chronic Hepatitis B Treatment

Healthcare Analyst Yee holds a conference call with CEO Blatt, CFO Calhoun and CMO Achneck on November 7 at 1 pm hosted by Jefferies. Webcast Link ...

Aligos Therapeutics participates in a conference call with Jefferies

09:30 EST Aligos Therapeutics (ALGS) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...

Aligos Therapeutics trading halted, volatility trading pause

10:21 EST Aligos Therapeutics (ALGS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

Aligos Therapeutics trading resumes

Healthcare Analysts discuss the recently-held AASLD Meeting (relevant companies ABUS HOOK BRNS VIR GSK (GSK) ALGS GILD) and catch-up on Chronic Hep...

JMP Securities healthcare analysts hold an analyst/industry conference call

09:38 EST Aligos Therapeutics (ALGS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

09:33 EST Aligos Therapeutics (ALGS) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...

13:52 EST Aligos Therapeutics (ALGS) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...

13:57 EST Aligos Therapeutics (ALGS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

Aligos Therapeutics (ALGS) shares are lower in afternoon trading after the company earlier announced "positive" data from one late-breaker oral and...

Aligos Therapeutics down 8% after data presented at The Liver Meeting

ABUS

BRNS

GILD

HOOK

Press Releases

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Aligos Therapeutics to Present at Investor Conferences in October

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Comments

Aligos Therapeutics

Aligos Therapeutics (ALGS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga